Assessing Porcine Gastric and Trachea Mucin Antimicrobial Activity Against Pseudomonas Aeruginosa

dc.contributor.advisorYang, Sydney
dc.contributor.advisorDuncan, Gregg
dc.contributor.authorSokol, Zoe
dc.date.accessioned2024-04-11T12:02:32Z
dc.date.available2024-04-11T12:02:32Z
dc.date.issued2024
dc.description.abstractMucus is present throughout the human body, lining all wet epithelia, making it a native, familiar material to the innate immune system. The biocompatibility of mucus opens the possibility for therapeutic applications. Existing research has shown that exposure to mucus triggers the downregulation of virulence genes in some bacteria species and rapidly disintegrates biofilms. The aim of this project is to test the innate antimicrobial activity of porcine gastric mucin (PGM) and porcine trachea mucin (PTM) against Pseudomonas aeruginosa. We examined the antimicrobial activity of mucins by quantifying bacteria growth and viability at numerous time points after mucin treatment. To test this hypothesis, PAO1 cultures were grown in LB broth overnight. Mucin was added to the planktonic PAO1 cultures at various concentrations, 8%, 4%, 2%, 1%, and 0.5% w/v, with each concentration tested in triplicates. At the 3 hr, 6 hr, and 24 hr timepoints after mucin addition, samples were taken from each culture, diluted, and spot-plated. The plates were grown overnight and counted the next day to calculate the colony-forming units. Preliminary results suggest that increasing mucin concentration correlates with decreased bacterial growth, as hypothesized. Additionally, PGM possibly shows a greater degree of antimicrobial effect than PTM. This research has a great potential impact. Pseudomonas aeruginosa is an opportunistic pathogen often developing antibiotic resistance making it extremely difficult to treat and a high priority for novel treatment development. Therefore, a novel treatment method against P. aeruginosa can have broad implications and improve bacterial infection treatments.
dc.description.sponsorshipThis material is based upon work supported by NIH R21 Grant No. EB030834. ZS is supported by the University of Maryland ASPIRE program. SY is supported by the University of Maryland Clark Doctoral Fellowship and the National Science Foundation Graduate Research Fellowship Program under Grant No. DGE 1840340.
dc.identifierhttps://doi.org/10.13016/nsru-t086
dc.identifier.urihttp://hdl.handle.net/1903/32417
dc.language.isoen_US
dc.relation.isAvailableAtDigital Repository at the University of Maryland
dc.relation.isAvailableAtUniversity of Maryland (College Park, Md)
dc.relation.isAvailableAtOffice of Undergraduate Research
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United Statesen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/
dc.subjectBioengineering
dc.subjectENGR
dc.subjectRespiratory NanoBioengineering (RnB) Lab
dc.subjectASPIRE
dc.subjectantimicrobial porcine mucin
dc.titleAssessing Porcine Gastric and Trachea Mucin Antimicrobial Activity Against Pseudomonas Aeruginosa
dc.typeOther
local.equitableAccessSubmissionNo

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2024_URD_Sokol_Zoe.pdf.pdf
Size:
1.12 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.55 KB
Format:
Item-specific license agreed upon to submission
Description: